Reading TOI? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track TOI free→Reading TOI? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track TOI free→QuarterlyIQ Insights · TOI
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
of a Current Report on Form 8-K filed on November 6, 2025, regarding a cybersecurity incident affecting a software service provider (“Vendor”) utilized by the Company. At the time of the prior voluntary disclosure, the Vendor had indicated that investigation was still ongoing and it could not yet confirm any evidence that any patient personal information was compromised as a result of this incident. However, on May 20, 2026, Kroll, who is the third-party administrator for the Vendor, notified…
Results of Operations and Financial Condition On May 7, 2026, The Oncology Institute, Inc. (the "Company") issued a press release announcing its financial results for the three months ended March 31, 2026 and certain other financial information. A copy of the press release is furnished hereto as Exhibit 99.1, which is incorporated by reference herein. The information contained in
Results of Operations and Financial Condition On March 12, 2026, The Oncology Institute, Inc. (the "Company") issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2025 and certain other financial information. A copy of the press release is furnished hereto as Exhibit 99.1, which is incorporated by reference herein. The information contained in
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (d) Appointment of New Director Through action taken by Unanimous Written Consent, effective February 23, 2026, the Board of Directors (the “Board”) of The Oncology Institute, Inc. (the “Company”) filled a vacancy on the Board by appointing Kimberly Tzoumakas to the Board. After conducting appropriate due diligence, the Nominating and Corporate Gov…
Results of Operations and Financial Condition. On January 12, 2026, The Oncology Institute, Inc. (the “Company”) issued a press release reaffirming the Company’s 2025 financial guidance and providing the Company’s preliminary 2026 financial outlook and certain additional longer-term financial guidance. A copy of the press release is furnished hereto as Exhibit 99.1, which is incorporated by reference herein. The information contained in this Item 2.02, including Exhibit 99.1, is furnished and…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (d) Appointment of New Director Through action taken by Unanimous Written Consent, effective January 2, 2026, the Board of Directors (the “Board”) of The Oncology Institute, Inc. (the “Company”) filled a vacancy on the Board by appointing Mark D. Stolper to the Board. After conducting appropriate due diligence, the Nominating and Corporate Governan…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On November 26, 2025, Gabriel Ling resigned from the Board of Directors of The Oncology Institute, Inc. (the “Company”), effective on December 1, 2025. Mr. Ling’s resignation is not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.
Results of Operations and Financial Condition On November 13, 2025, The Oncology Institute, Inc. (the "Company") issued a press release announcing its financial results for the three months ended September 30, 2025 and certain other financial information. A copy of the press release is furnished hereto as Exhibit 99.1, which is incorporated by reference herein. The information contained in
Regulation FD Disclosure. On November 3, 2025, The Oncology Institute, Inc. (the “Company”) determined that a cybersecurity incident affecting an information technology software provider would potentially delay fee-for-service collections. Based on the Company's current assessment, this incident is expected to result in a brief immaterial delay in the collection of some claims in the Company's fee-for-service segment. To date, the software provider has not indicated to the Company that there…
Results of Operations and Financial Condition On August 13, 2025, The Oncology Institute, Inc. (the "Company") issued a press release announcing its financial results for the three months ended June 30, 2025 and certain other financial information. A copy of the press release is furnished hereto as Exhibit 99.1, which is incorporated by reference herein. The information contained in
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 8, 2025, Richard Barasch resigned from the Board of Directors of The Oncology Institute, Inc. (the “Company”), effective August 12, 2025. Mr. Barasch’s resignation is not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. Anne McGeorge will replace Mr. Barasch as Chai…
Results of Operations and Financial Condition On May 14, 2025, The Oncology Institute, Inc. (the "Company") issued a press release announcing its financial results for the three months ended March 31, 2025 and certain other financial information. A copy of the press release is furnished hereto as Exhibit 99.1, which is incorporated by reference herein. The information contained in
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On May 2, 2025, Jeremy Castle provided notice of his resignation as Chief Operating Officer of The Oncology Institute, Inc. (the “Company”), effective as of May 30, 2025. Mr. Castle’s resignation was not the result of any disagreement between Mr. Castle and the Company on any matter relating to the Company’s operations, policies or practices.
Entry into a Material Definitive Agreement. On March 26, 2025, The Oncology Institute, Inc. (the “Company”) closed its previously announced private placement (the “Private Placement”) of an aggregate of: (i) 12,006,510 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), (ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to an aggregate of 2,886,614 shares of Common Stock and (iii) accompanying common warrants (the “Common War…
The offer and sale of the Securities, the shares of Preferred Stock and the shares of Common Stock underlying the Warrants and shares of Preferred Stock have not been registered under the Securities Act of 1933, as amended (the “Securities Act”). The Company issued the Securities and shares of Preferred Stock in reliance on exemptions from registration provided for under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D, or in the case of the Exchange Section 3(a)(9) of the S…
Regulation FD Disclosure. On March 24, 2025, the Company issued a press release announcing the Private Placement and the Exchange, a copy of which is attached as Exhibit 99.1 hereto and incorporated herein by reference. The information contained in this Item 7.01, including Exhibit 99.1, is furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, and such information shall not be deemed to be incor…
Material Modification to Rights of Security Holders To the extent required by
The offer and sale of the Securities, the shares of Preferred Stock and the shares of Common Stock underlying the Warrants and shares of Preferred Stock have not been registered under the Securities Act of 1933, as amended (the “Securities Act”). The Company issued the Securities and shares of Preferred Stock in reliance on exemptions from registration provided for under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D, or in the case of the Exchange Section 3(a)(9) of the S…
Entry into a Material Definitive Agreement. Securities Purchase Agreement On March 24, 2025, The Oncology Institute, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain investors (the “Purchasers”), including existing investors, as well as members of the Company’s management team and board of directors, and entities affiliates with members of the Company’s board of directors. The Purchase Agreement provides for the sale and issuance by the…
Results of Operations and Financial Condition On March 24, 2025, The Oncology Institute, Inc. (the "Company") issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2024 and certain other financial information. A copy of the press release is furnished hereto as Exhibit 99.1, which is incorporated by reference herein. The information contained in
Entry into a Material Definitive Agreement. On February 26, 2025, The Oncology Institute, Inc. (the “Company”), the other loan parties party thereto, the lenders party thereto and Deerfield Partners, L.P. (the “Agent”), entered into that certain Limited Consent and Amendment No. 1 to Facility Agreement (the “Consent and Amendment”), which amends the Company’s existing Facility Agreement, dated as of August 9, 2022, by and among the Company, the other loan parties party thereto from time to ti…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.